Respiratory Pathogens Data Aug 03 - Nov 10 2018

Week Beginning	InfA-H1	InfA-H3	2009 H1N1	Inf B	RSV	All Para	EV / Rhino	Meta pneumo	Adeno	All Corona	Bocca	Myco plasma	Chla mydia	Total Pos	POS FLU	Total	ACL %FLU	US %FLU	IL/WI PCR	Sofia EIA
NOV 9	0	0	1	0	23	28	78	4	7	5	1	6	2	155	1	458	0.2	n/a	n/a	1.5
OCT 26	0	0	2	0	18	23	93	1	8	2	3	6	1	157	2	506	0.4	0.9	0.7	1.6
OCT 19	0	0	1	0	12	25	93	1	5	3	3	6	0	149	1	415	0.2	0.8	0.5	
OCT 12	0	0	0	0	11	17	111	1	4	3	0	1	1	149	0	478	0.0	0.6	0.4	
OCT 6	0	0	1	0	4	15	101	2	5	1	2	2	0	133	1	435	0.2	0.8	0.5	1.5
SEP 28	0	0	0	0	1	10	103	2	1	2	2	3	0	124	0	410	0.0	0.9	0.6	1.5
SEP 21	0	0	0	0	1	10	107	1	6	3	3	0	2	133	0	388	0.0	0.8	0.9	0.9
SEP 14	0	0	0	0	2	9	135	0	2	0	5	1	0	154	0	415	0.0	0.7	1.0	0.7
SEP 7	0	0	0	0	0	9	113	0	4	0	1	1	0	128	0	370	0.0	1.7	0.5	0.9
AUG 31	0	0	1	0	1	6	84	1	3	1	5	0	0	102	1	338	0.3	1.8	0.7	0.7
AUG 24	0	1	0	0	1	3	67	1	0	0	2	0	0	75	1	258	0.4	1.6	0.2	6.9
AUG 17	0	0	0	0	0	8	42	1	1	2	1	0	1	56	0	267	0.0	0.3	1.2	2.3
AUG 10	0	0	2	0	0	6	55	2	2	1	1	1	0	70	2	246	0.8	0.9	0.2	3.4
AUG 3	0	0	0	0	0	5	35	1	5	0	0	0	0	46	0	229	0.0	1.0	0.2	0.0

Flu PCR
% Rate


ACL RESP. PANEL - POSITIVITY RATE All 2018 - 33.8%
All Corona
Chla mydia
Myco plasma
All Para
Adeno
Meta pneumo
EV / Rhino
RSV
Inf B
InfA-H3
2009 H1N1
InfA-H1
Bocca
220
170
120
70
20
-30
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 6
OCT 12
OCT 19
OCT 26
NOV 9


ACL Influenza PCR POS 0.2%
POS FLU
Total
229
246
267
258
338
370
415
388
410
435
478
415
506
458
0
2
0
1
1
0
0
0
0
1
0
1
2
1
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 6
OCT 12
OCT 19
OCT 26
NOV 9
700
600
500
400
300
200
100
0
-100


ACL FLUAG EIA POS 1.5%
Total
POS EIA
32
29
43
58
137
227
288
435
467
535
613
630
645
729
0
1
1
4
1
2
2
4
7
8
6
8
10
11
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 6
OCT 12
OCT 19
OCT 26
NOV 9
850
750
650
550
450
350
250
150
50
-50

Correlation between RPPNL (FLU PCR) and Sofia (FLUAG)

In the last three weeks 306 samples were tested by both methods most of them negative only 2 samples were positive by EIA. **Accuracy for the beginning of the season is 99.7%**

Oct 14 2018 to Nov 08 2018				
FLUAG (Sofia) vs RPPNL (PCR) correlation				
		RPPNL		
		+	-	Total
FluAG	+	1	0	1
	-	1	304	305
			Total	306
%				
50.0	Clinical Sensitivity			
100.0	Clinical Specificity			
100.0	Positive Predictive Value (PPV)			
99.7	Negative Predicative Value (NPV)			
99.7	Accuracy			

Both positive samples were run 72 h apart

CDC Nov 3, 2018 **Positivity rate 0.9% -** **Flu A – 74% , Flu B – 26%**



FLUVIEW

CDC

A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists*

Week Ending Nov 03, 2018 - Week 44



Influenza Activity Estimates

- No Activity
- Sporadic
- Local Activity
- Regional
- Widespread
- No Report

*This map indicates geographic spread and does not measure the severity of influenza activity.

FluView

A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Influenza-Like Illness (ILI) Activity Level Indicator Determined by Data Reported to ILINet

2018-19 Influenza Season Week 44 ending Nov 03, 2018



ILI Activity Level

- High
- Moderate
- Low
- Minimal
- Insufficient Data

*This map uses the proportion of outpatient visits to healthcare providers for influenza-like illness to measure the ILI activity level within a state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high activity levels.
*Data collected in ILINet may disproportionately represent certain populations within a state, and therefore may not accurately depict the full picture of influenza activity for the whole state.
*Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map are based on reports from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received.
*Differences in the data presented by CDC and state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.
*For the data download you can use Activity Level for the number and Activity Level Label for the text description.

The most prevalent target as **Nov 2nd were VZV and EV 7.4%**



The most prevalent targets as **Nov 2nd** was **Giardia**



The most prevalent target as **Nov 2nd** was **Norovirus**



	BV-Bacterial vagionosis	Candida albicans	Candida galbrata	Candida kruzei	T. vaginalis	M. genitalium	M. hominis	U. parvum	TOTAL % POS
% pos	**21.3**	**13.0**	**2.0**	**0.4**	**2.9**	**0.1**	**6.7**	**18.5**	**64.3**



Neuraminidase Inhibitors **Resistance** in Samples Collected – May 20- Nov 03, 2018,

Per CDC website	Oseltamivir		Zanamivir		Peramivir	
	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)
Influenza A (H1N1)pdm09	70	0	70	0	70	0
Influenza A (H3N2)	57	0	57	0	57	0
Influenza B	44	0	44	0	44	0